Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

NCT07700446 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG: Upadacitinib

Sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives